NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









BioEclosion

BioEclosion

Private
Cerdanyola del VallèsHealthcare & Life Scienceshttps://bioeclosion.com/

Last Round

Seed

Dec 1, 2024

Est. Valuation

$2.96M

Total Funding Raised

$1.22M

Company Overview

BioEclosion is a healthtech company that develops a patented in-vitro diagnostic device for rapid diagnostics in human health, veterinary, and food safety.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment, Sensors, Environmental Monitoring

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

point-of-care diagnosticsin-vitro diagnosticIVDrapid diagnosticslab-on-a-chipbiosensor technologyPOC testingveterinary diagnosticshandheld diagnosticsfood safety testingdiagnostic cartridgesportable diagnostic readerimmunoassaymobile diagnosticsmagneto-electrochemical immunoassayneonatal sepsis screeningavian influenza teston-farm testing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioEclosion Comparables

Compare BioEclosion with similar companies based on industry and business-model similarity.

BioEclosion comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
StataDx, Inc.
78%
Alveo Technologies
78%
GRIP Molecular Technologies
72%

BioEclosion Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedDec 1, 2024
GrantApr 5, 2023
AcceleratorMay 17, 2021
GrantDec 1, 2020
GrantOct 1, 2017

Key People

Founding team and executive leadership

Jofre Ferrer-Dalmau

CEO & CoFounder

Founding Team

BioEclosion Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2021

    Participated in MassChallenge Switzerland's accelerator program.

  • Oct 1, 2017

    Received grant funding to support operations.

BioEclosion Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BioEclosion Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BioEclosion's valuation, stock price, and market status.

Firmographic Details

HeadquartersCerdanyola del Vallès
Employee Range7
Year Founded2016
Last FundingDec 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.